Health Condition 1: null- Newly diagnosed Hodgkin lymphoma patients
Conditions
Sponsors
Tata Memorial Hospital
Not Any
Eligibility
Inclusion criteria
Inclusion criteria: 1 Newly diagnosed classical Hodgkin lymphoma (Early stage unfavorable and Advanced stage) 2 Treated with ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) 3 age > 15 years
Exclusion criteria
Exclusion criteria: 1 Early Stage Favourable 2 HIV positive patient 3 Patients unwilling to comply with the study procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To correlate iPET response with biomarker responseTimepoint: 1 At baseline 2 After 2 cycles of chemotherapy 3 At the end of therapy 4 At the end of 2 yrs | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of biomarkers response with the PFS at the end of 2 yearsTimepoint: 1 At the end of therapy 2 At the end of 2 yrs;Correlation of End of Therapy PET with biomaker responseTimepoint: 1 At baseline 2 After 2 cycles of chemotherapy 3 At the end of therapy | — |
Countries
India
Contacts
Public ContactDr Raajit Chanana
Tata Memorial Center
Outcome results
None listed